Related Experiment Video
Updated: May 20, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
Published on: September 10, 2018
Effects of dronabinol on morphine-induced dopamine-related behavioral effects in animals
Tomohisa Mori1, Masahiro Shibasaki, Minako Abe
1Department of Toxicology, School of Pharmacy, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
Abstract:
The present study examined the effects of dronabinol, a United States FDA-approved synthetic cannabinoid receptor agonist, on morphine (a prototypic μ-opioid receptor agonist)-induced dopamine-related behaviors in animals. Dronabinol suppressed the rewarding effects of morphine in rats and its emetic effects in ferrets. Furthermore, the morphine-induced increase in dopamine release from the nucleus accumbens was significantly attenuated by dronabinol, which indicated that the suppressive effects of dronabinol on morphine-induced behaviors are at least in part mediated by regulation of the dopaminergic system. Since cannabinoid receptor agonists have been shown to enhance the antinociceptive effects of morphine, the use of dronabinol as an adjuvant could be useful for preventing the adverse effects of μ-opioid receptor agonists when used to control pain.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Opioid Receptors: Overview
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Analgesics: Morphine and Other Natural Cogeners
Drug Abuse and Addiction: Pharmacological Phenomena
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

